MRT-8102
Asset
Molecular glue degrader of NEK7 inhibiting NLRP3 inflammasome activation
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- NLRP3 inflammasome
- 3
- Indications
- 0
- Trials
- 1
- Developer
Indications
3Cardiovascular risk in obesity
Phase 1, longevity.technology, 2 Oct 2026
Heart inflammation
Phase 1, longevity.technology, 2 Oct 2026
Obese subjects with elevated cardiovascular risk
Phase 1, longevity.technology, 2 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Evidence for its targets2
- Competitors12
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.